MILLENDO THERAPEUTICS

📍 Ann Arbor, United States👥 6 employees💰 Last funded 2018
Biotechnology🌐 millendo.com
Website LinkedIn
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in MILLENDO THERAPEUTICS?
MILLENDO THERAPEUTICS has 2 investors on record on gritt.io.
When did MILLENDO THERAPEUTICS last raise funding?
The most recent investment in MILLENDO THERAPEUTICS recorded on gritt.io was in 2018.
What industry is MILLENDO THERAPEUTICS in?
MILLENDO THERAPEUTICS operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is MILLENDO THERAPEUTICS based?
MILLENDO THERAPEUTICS is headquartered in Ann Arbor, United States.